Regulatory T cell frequency in patients with melanoma with different disease stage and course,and modulating effects of high-dose interferon-alpha 2b treatment. (Articolo in rivista)

Type
Label
  • Regulatory T cell frequency in patients with melanoma with different disease stage and course,and modulating effects of high-dose interferon-alpha 2b treatment. (Articolo in rivista) (literal)
Anno
  • 2010-01-01T00:00:00+01:00 (literal)
Alternative label
  • Ascierto PA, Napolitano M, Celentano E, Simeone E, Gentilcore G, Daponte A, Capone M, Caraco C, Calemma R, Beneduce G, Cerrone M, De Rosa V, Palmieri G, Castello G, Kirkwood JM, Marincola FM, Mozzillo N. (2010)
    Regulatory T cell frequency in patients with melanoma with different disease stage and course,and modulating effects of high-dose interferon-alpha 2b treatment.
    in Journal of translational medicine (Online)
    (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori
  • Ascierto PA, Napolitano M, Celentano E, Simeone E, Gentilcore G, Daponte A, Capone M, Caraco C, Calemma R, Beneduce G, Cerrone M, De Rosa V, Palmieri G, Castello G, Kirkwood JM, Marincola FM, Mozzillo N. (literal)
Pagina inizio
  • 76 (literal)
Pagina fine
  • 79 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume
  • 8 (literal)
Rivista
Note
  • PubMed (literal)
  • Scopus (literal)
  • ISI Web of Science (WOS) (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni
  • 1Unit of Medical Oncology and Innovative Therapy, Melanoma Cooperative Group, National Tumor Institute, Naples, Italy, 2Institute of Biomolecular Chemistry-CNR, Trav. La Crucca, 3 - Baldinca Li Punti, Sassari, Italy, 3Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA and 4Department of Transfusion Medicine, Clinical Center, National Institute of Health, Bethesda, MD, USA (literal)
Titolo
  • Regulatory T cell frequency in patients with melanoma with different disease stage and course,and modulating effects of high-dose interferon-alpha 2b treatment. (literal)
Abstract
  • Background: High-dose interferon-alpha 2b (IFN-± 2b) is the only approved systemic therapy in the United States for the adjuvant treatment of melanoma. The study objective was to explore the immunomodulatory mechanism of action for IFN-± 2b by measuring serum regulatory T cell (Treg), serum transforming growth factor-b (TGF-b), interleukin (IL)-10, and autoantibody levels in patients with melanoma treated with the induction phase of the high-dose IFN-± 2b regimen. Methods: Patients with melanoma received IFN-± 2b administered intravenously (20 MU/m2 each day from day 1 to day 5 for 4 consecutive weeks). Serum Treg levels were measured as whole lymphocytes in CD4+ cells using flow cytometry while TGF-b, IL-10, and autoantibody levels were measured using enzyme-linked immunosorbent assays. Results: Twenty-two patients with melanoma received IFN-± 2b treatment and were evaluated for Treg levels. Before treatment, Treg levels were significantly higher in patients with melanoma when compared with data from 20 healthy subjects (P = 0.001; Mann-Whitney test). Although a trend for reduction of Treg levels following IFN-± 2b treatment was observed (average decrease 0.29% per week), statistical significance was not achieved. Subgroup analyses indicated higher baseline Treg levels for stage III versus IV disease (P = 0.082), early recurrence versus no recurrence (P = 0.017), deceased versus surviving patients (P = 0.021), and preoperative neoadjuvant versus postoperative adjuvant treatment groups (not significant). Following IFN-± 2b therapy, there was a non-statistically significant trend for a decrease in Treg levels by week in patients with melanoma. No significant effects were observed on the levels of TGF-b, IL-10, and autoantibodies in patients with melanoma treated with IFN-± 2b. Conclusions: Patients with melanoma in this study showed increased basal levels of Treg that may be relevant to their disease and its progression. Treg levels shifted in patients with melanoma treated with IFN-± 2b, although no firm conclusions regarding the role of Tregs as a marker of treatment response or outcome can be made at present. (literal)
Prodotto di
Autore CNR

Incoming links:


Prodotto
Autore CNR di
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi
data.CNR.it